Frequency Therapeutics Stock Forecast, Price & News

+0.68 (+7.17 %)
(As of 04/13/2021 05:22 PM ET)
Today's Range
Now: $10.17
50-Day Range
MA: $29.17
52-Week Range
Now: $10.17
Volume930,929 shs
Average Volume1.26 million shs
Market Capitalization$347.59 million
P/E RatioN/A
Dividend YieldN/A
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Frequency Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FREQ
Year FoundedN/A



Sales & Book Value

Annual Sales$28.95 million
Book Value$5.44 per share


Net Income$-18,750,000.00


Market Cap$347.59 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable


See More Headlines


Overall MarketRank

1.53 out of 5 stars

Medical Sector

471st out of 2,019 stocks

Pharmaceutical Preparations Industry

226th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
+0.68 (+7.17 %)
(As of 04/13/2021 05:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FREQ News and Ratings via Email

Sign-up to receive the latest news and ratings for FREQ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Frequency Therapeutics (NASDAQ:FREQ) Frequently Asked Questions

Is Frequency Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Frequency Therapeutics stock.
View analyst ratings for Frequency Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Frequency Therapeutics?

Wall Street analysts have given Frequency Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Frequency Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Frequency Therapeutics?

Frequency Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,960,000 shares, an increase of 91.3% from the March 15th total of 4,160,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is presently 6.1 days. Approximately 27.0% of the company's shares are short sold.
View Frequency Therapeutics' Short Interest

When is Frequency Therapeutics' next earnings date?

Frequency Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Frequency Therapeutics

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its earnings results on Sunday, March, 28th. The company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.05. Frequency Therapeutics had a negative net margin of 68.59% and a negative trailing twelve-month return on equity of 12.56%.
View Frequency Therapeutics' earnings history

How has Frequency Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Frequency Therapeutics' stock was trading at $18.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FREQ stock has decreased by 45.1% and is now trading at $10.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for FREQ?

3 equities research analysts have issued 1 year price objectives for Frequency Therapeutics' stock. Their forecasts range from $20.00 to $56.00. On average, they expect Frequency Therapeutics' stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 263.8% from the stock's current price.
View analysts' price targets for Frequency Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Frequency Therapeutics' key executives?

Frequency Therapeutics' management team includes the following people:
  • Mr. David L. Lucchino, Co-­Founder, CEO, Pres, Treasurer, Sec. & Director (Age 52, Pay $850.67k)
  • Dr. Christopher R. Loose, Co­-Founder & Chief Scientific Officer (Age 41, Pay $616.44k)
  • Dr. Carl P. LeBel, Chief Devel. Officer (Age 62, Pay $611.62k)
  • Mr. William J. McLean, Co-­Founder and VP of Biology & Regenerative Medicine
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 52)
  • Mr. Richard J. Mitrano, VP of Fin. & Operations (Age 51)
  • Dr. Jeff Hrkach, Sr. VP of Technology Devel. (Age 55)
  • Mr. Michael D. Bookman J.D., Gen. Counsel & Sec.
  • Ms. Wendy S. Arnold, Chief People Officer (Age 49)
  • Dr. Dana C. Hilt, Chief Medical Officer (Age 68)

Who are some of Frequency Therapeutics' key competitors?

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX).

When did Frequency Therapeutics IPO?

(FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Frequency Therapeutics' stock symbol?

Frequency Therapeutics trades on the NASDAQ under the ticker symbol "FREQ."

How do I buy shares of Frequency Therapeutics?

Shares of FREQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Frequency Therapeutics' stock price today?

One share of FREQ stock can currently be purchased for approximately $10.17.

How much money does Frequency Therapeutics make?

Frequency Therapeutics has a market capitalization of $347.59 million and generates $28.95 million in revenue each year. The company earns $-18,750,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Frequency Therapeutics have?

Frequency Therapeutics employs 43 workers across the globe.

What is Frequency Therapeutics' official website?

The official website for Frequency Therapeutics is

Where are Frequency Therapeutics' headquarters?

Frequency Therapeutics is headquartered at 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801.

How can I contact Frequency Therapeutics?

Frequency Therapeutics' mailing address is 19 PRESIDENTIAL WAY SUITE 203, WOBURN MA, 01801. The company can be reached via phone at 866-389-1970 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.